Nanosys Licenses Nanowire Technology to QuantuMDx | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosys today said that it has licensed patents and patent applications covering the use of nanowires for biosensors to QuantuMDx Group.

The non-exclusive pact allows QuantuMDx to use the technology worldwide for DNA sequencing and biomarker detection applications. In exchange, QuantuMDx paid Palo Alto, Calif.-based Nanosys an upfront license fee and will make downstream royalty payments.

Further terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.